Clinical Trials

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma


Study ID
Alliance A091605

NCT Number
NCT03304639 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0574

Principle Investigator
Dr. Andrew Pecora

Phase
II

Sponsor
Alliance


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now